Anti-CD19 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphomas
This is a single arm, open-label, single center study to determine the safety and efficacy of Anti-CD19 CAR-T cells in patients with relapsed or refractory acute lymphoblastic leukemia and Lymphomas.
Acute Lymphoblastic Leukemia ,Lymphomas
BIOLOGICAL: Anti-CD19 CAR-T
Overall responce rate(ORR), Assessment of ORR (ORR = CR+PR ) at 2 months of treatment, 2 years|Overall survival (OS), Assessment of OS(Overall survival) at 6 months of treatment, 2 years|Progression-free survival (PFS), Assessment of PFS(Progression-free survival ) at 6 months of treatment, 2 years|minimal residual disease（MRD）, Assessment of MRD negative overall response rate at 3 months of treatment, 2 years
Safety (incidence of adverse events defined as dose-limited toxicity), Occurrence of study related adverse events defined as NCI CTCAE 4.0 \> grade 3 possibly, probably, or definitely related to study treatment., Study treatment until Week 24|Expression of CD19 CART cells, Expression of CD19 CART cells detected by flow cytometry in blood and bone marrow., 2 years|Detection of CD19 CART cells, Detection of CD19 CART cells in blood, bone marrow by Quantitative Polymerase Chain Reaction (q-PCR)., 2 years
CD19 has been extensively evaluated as a therapeutic target for relapsed or refractory B cell malignancy by chimeric antigen receptor T cell therapy,this is a single arm, open-label, single center study to determine the safety and efficacy of Anti-CD19 CAR-T cells in patients with refractory acute lymphoblastic leukemia and Lymphomas.